Select Medical Holdings (SEM) announced that its stockholders have approved the proposed acquisition by a consortium led by co-founder and executive Robert A. Ortenzio, CFO Martin F. Jackson, and private equity firm WCAS (Welsh, Carson, Anderson & Stowe). The vote clears the largest remaining hurdle for the go-private transaction, which takes the company off public markets with founding management rolling equity alongside a major healthcare-focused PE backer.

SEM is a $5.5B revenue business growing at roughly 5% year-over-year with a thin 3.9% net margin and $1.16 in diluted EPS. The lean margins mean the deal thesis likely centers on operational restructuring and debt-capacity improvements away from public scrutiny — a classic WCAS playbook in healthcare services.

With the stockholder vote done, the remaining risks are regulatory clearance (antitrust) and customary closing conditions. The trade now is a pure merger arbitrage setup: the spread between where SEM trades and the deal price reflects time value and residual deal-break risk. Given management is leading the buyer consortium, the probability of a walkaway or bid reduction is structurally lower than a third-party acquirer scenario.

The bear case is deal timeline slippage or a surprise regulatory challenge, which could widen the arb spread and pressure the stock. The bull case is a clean, fast close that delivers the full deal consideration, letting arb players capture the remaining spread. Watch for a Form 8-K or press release announcing a closing date, which would be the next material catalyst.